Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial. The Danish ...

Novo Nordisk has taken another step towards ... to buy US biotech Corvidia Therapeutics and its lead drug for chronic kidney disease (CKD). The deal starts with $725 million in an upfront cash ...

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...

Obesity is not just a lifestyle issue but a chronic disease that requires sustained medical intervention, said Vikrant Shrotriya, Managing Director of Novo Nordisk India, at the India Today ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...